Report Highlights

The U.S. Role in the Global Eye Health Supplement Supply Chain

The United States functions primarily as a high-value formulator and consumer market rather than a raw ingredient producer. Domestic manufacturing concentrates in New Jersey, California, and Utah, where contract manufacturers and brand owners finish softgels, gummies, and tablets. Imports of lutein, zeaxanthin, and fish oil arrive mainly through the ports of Los Angeles, Long Beach, and New York/New Jersey, with inbound volumes from China, India, and Norway dominating raw material flows.

Export volumes remain modest, with finished supplements shipped mainly to Canada, Mexico, and the United Kingdom under USMCA and bilateral frameworks. The principal vulnerability is import dependence for botanical and marine inputs, which exposes manufacturers to Chinese and Indian export controls and to freight disruption across the Pacific and Suez routes. Value-add strength remains high: AREDS2 research sponsored by the National Eye Institute set the global formulation standard for lutein and zeaxanthin.

Growth Drivers for U.S. Eye Health Supplement Trade and Production

Three forces are expanding domestic production capacity. Contract manufacturers in Utah and New Jersey are adding softgel and gummy lines to serve private-label orders from national pharmacy chains, reducing reliance on finished-goods imports. Demand from adults with heavy screen exposure is pushing formulators toward higher-purity lutein and zeaxanthin blends, and certificates of analysis now accompany most lutein purchase orders.

Import substitution is also accelerating in omega-3 processing. Refining capacity is growing along the Gulf Coast, where firms are sourcing domestic menhaden, though volumes remain small against Norwegian and Peruvian supply. Demographics supply the third driver: millions of Americans over 65 carry age-related macular degeneration risk, and Medicare coverage excludes most vitamin purchases, so spending falls on out-of-pocket supplements.

Supply Chain Risks and Trade Barriers for U.S. Eye Health Supplements

Raw material dependency is the principal exposure. Lutein from marigold extract depends on concentrated Asian processing, and 2025 reciprocal tariffs on Chinese and Indian goods raised landed costs faster than brands could reprice shelf prices. Many contracts lack tariff pass-through clauses. Fish oil supply also tracks Peruvian anchovy harvest quotas, which swing sharply with El Niño cycles and disrupt contract pricing.

Logistics gaps compound these risks. West Coast port congestion and container rate volatility lengthen transit times for shipments routed through the Port of Los Angeles and Long Beach. Currency exposure is contained because most U.S. contracts settle in dollars, yet Indian and Peruvian suppliers price in local currency, so brands carry hedging costs. Regulatory exposure under DSHEA also means that a single claims dispute can halt shipments at the border.

Trade and Investment Opportunities in U.S. Eye Health Supplements

Canada and Mexico offer the nearest export expansion path under USMCA, and Mexico's growing pharmacy chains absorb American-branded softgels at premium price points. Inbound investment from Japanese and European ingredient producers into domestic lutein and astaxanthin fermentation capacity would cut tariff exposure and shorten lead times for American brands. Kemin, headquartered in Des Moines, already markets FloraGLO lutein to domestic formulators, demonstrating local ingredient demand.

Logistics hub development offers a second opening. Houston and Savannah have capacity to host bonded warehousing for botanical inputs, allowing blenders to hold lutein and fish oil stock for Latin American distribution. Private-label contract manufacturers in Utah also have room to add eye-specific cGMP lines, which reduces reliance on Asian finished goods for pharmacy chains.

Market at a Glance

Leading Market Participants

• Bausch + Lomb
• Alcon
• Pharmavite
• Nature's Bounty Co.
• Perrigo Company
• Nestlé Health Science
• Amway
• Life Extension
• Thorne HealthTech
• Herbalife

Regulatory and Trade Policy Environment

The Dietary Supplement Health and Education Act of 1994 governs supplements, allowing structure and function claims without FDA pre-approval, while disease claims remain prohibited. Manufacturing must comply with FDA current good manufacturing practice rules under 21 CFR Part 111, and new dietary ingredients require notification at least 75 days before marketing. Eye health claims referencing AREDS2 outcomes must be carefully phrased, and Federal Trade Commission rules separately police advertising substantiation.

Trade policy turns on tariffs and agreements. USMCA provides duty-free access for qualifying originating goods from Canada and Mexico, while Section 301 duties on Chinese goods and 2025 reciprocal tariffs on Indian imports raise landed costs for lutein and other extract inputs. Customs classification determines applicable duty rates, so importers should file binding rulings with U.S. Customs and Border Protection to fix tariff treatment in advance.

U.S. Eye Health Supplement Supply Chain Outlook to 2032

Domestic capacity will expand as contract manufacturers add softgel, gummy, and liquid lines in the Mountain West and Northeast. Nearshoring toward Mexico will absorb part of the finished-goods trade, while onshore lutein extraction grows as tariff costs for Chinese marigold extract rise. Brand owners that invest in U.S.-based cGMP lines by 2028 will capture the largest margin benefit.

Technology will reshape comparative advantage. Precision fermentation of zeaxanthin and astaxanthin in U.S. bioprocessing facilities offers a substitute for marigold extraction, removing dependence on Asian field supply. Algae-derived omega-3 production in the Southwest will further reduce fish oil import reliance, shifting the United States from net importer toward a regional supplier of marine-free inputs.